Exencial Wealth Advisors LLC Sells 503 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Exencial Wealth Advisors LLC lessened its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 5.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,049 shares of the medical research company’s stock after selling 503 shares during the period. Exencial Wealth Advisors LLC’s holdings in Laboratory Co. of America were worth $2,075,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. SouthState Corp bought a new position in shares of Laboratory Co. of America during the 3rd quarter valued at about $28,000. Fortitude Family Office LLC raised its position in Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the last quarter. Geneos Wealth Management Inc. raised its position in Laboratory Co. of America by 309.8% in the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after buying an additional 127 shares during the last quarter. Human Investing LLC acquired a new stake in Laboratory Co. of America in the 4th quarter valued at approximately $39,000. Finally, Kennebec Savings Bank acquired a new stake in Laboratory Co. of America in the 3rd quarter valued at approximately $42,000. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LH. Jefferies Financial Group lifted their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Piper Sandler lifted their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America lifted their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, Morgan Stanley boosted their price target on Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $268.38.

Insider Buying and Selling

In related news, EVP Der Vaart Sandra D. Van sold 1,314 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $251.30, for a total value of $330,208.20. Following the completion of the sale, the executive vice president now directly owns 2,171 shares in the company, valued at $545,572.30. The trade was a 37.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Adam H. Schechter sold 6,121 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total value of $1,497,319.02. Following the completion of the sale, the chief executive officer now owns 86,445 shares of the company’s stock, valued at $21,146,175.90. This trade represents a 6.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,000 shares of company stock valued at $3,449,757. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Stock Up 1.2 %

LH stock opened at $257.10 on Wednesday. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $21.52 billion, a PE ratio of 29.15, a PEG ratio of 1.71 and a beta of 1.07. Laboratory Co. of America Holdings has a 1-year low of $191.97 and a 1-year high of $258.59. The business’s 50 day simple moving average is $242.27 and its 200 day simple moving average is $233.19.

Laboratory Co. of America (NYSE:LH) last posted its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, research analysts anticipate that Laboratory Co. of America Holdings will post 16.01 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s payout ratio is presently 32.65%.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.